April 7, 2022 7:42am
A two-session pop follows a two-session dive, I stick to my view of anticipating the risks
Pre-open indications: 5 BUYS, 1 SELL and 1 Pimp/Pump/Promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts … I ask questions and note the indications of what could happen …
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -0.02% (-8 points), S&P futures are UP +0.16% (+7 points) and NASDAQ futures are UP +0.30% (+44 points)
U.S. stock futures are mixed, at times skipping to the downside on Thursday trying to recover from Wednesday’s sell-off,
European markets were mixed as volatility continued following details of the U.S. Federal Reserve’s monetary tightening plans and the ongoing war in Ukraine,
Asia-Pacific markets fell, with Japan’s Nikkei 225 shedding almost 2% to lead losses; as surging covid cases disrupt global supply chains.
Henry’omics:
Yesterday, the Dow dropped 144.07 points or -0.42%, joined by the S&P’s -43.97 points or -0.97% and followed by the Nasdaq -315.35 or -2.22%
RegMed Investors’ (RMi) closing bell: “uncertainty trips upside momentum. It will be a race to safe havens as risks shake not stir the cell and gene therapy sector share pricings.” … https://www.regmedinvestors.com/articles/12377
Ebb and flow –
Q2/22 – 2 positive and 2 negative close
Q1/22:
· March – 13 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... (35 to date -some dropped a couple added)
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS, POSSIBILITIES and POTENTIALS …
BUY for a possible bounce:
AxoGen (AXGN) closed down -$0.41 to $7.55 after Tuesday’s -$0.23 and Monday’s +$0.04 with a positive +$0.20 or +2.65% pre-open indication,
Beam Therapeutics (BEAM) closed down -$1.65 to $54.80 after Wednesday’s -$1.65, Tuesday’s -$5.90 and Monday’s +$2.41 with a positive +$0.29 or +0.53% pre-open indication
CRISPR Therapeutics (CRSP) closed down -$1.36 to $66.12 after Tuesday’s -$2.03 and Monday’s +$3.36 with a positive +$0.88 or +1.33%,
Editas Medicine (EDIT) closed down -$0.58 to $19.75 after Tuesday’s -$1.02 and Monday’s +$1.13 with a positive +$0.21 or +1.06% pre-open indication,
Regenxbio (RGNX) closed down -$0.59 to $33.78 after Tuesday’s -$0.67 with a positive +$1.68 or +4.97% pre-open indication
SELL:
Global Blood Therapeutics (GBT) closed down -$0.52 to $36.87 after Tuesday’s +$0.09 and Monday’s +$1.39 with a negative -$0.92 or -2.50%
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed down -$0.05 with 1,527 shares traded, after Tuesday’s +$0.59 with 8,743 shares trading, Monday +$0.49 with 8,809 shares traded, Friday’s flat with 16 shares traded and last Thursday’s -$0.10 with 124 shares traded. WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion? Also, WHY the pump of the volume to gain share appreciation – they have to reverse the multiple private placements (the priciest was $4.71) for a potential/proposed stock offering–.
The BOTTOM LINE: I think and feel the opposite of yesterday’s sell-off as I had abstained from any BUY/SELL initiative in the sector.
Again, it is all dependent on the stock market but, selling could continue.
My version of a relevant quote from IBD, “The major indexes and leading <cell and gene therapy> stocks will often rise on an escalator and come down on an elevator.”
Reiterating, keep positions small and diversified amid modest overall exposure to limit any fallout. Taking profits quickly and cutting losers quickly is still vital
Reiterating, “An odd quote that caught my eye and some feelings, “To paraphrase the Rolling Stones, you can't always get what you want, but sometimes you get what you need.”
Again, I reiterate, “I’m never totally wrong but, not always wholly right as there is no clear trend ….
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
